AC Immune reported new preliminary Phase 1 data for its TDP43-PET tracer ACI-19626, showing higher uptake in patients with ALS. The update is an early clinical-stage signal for the imaging program and supports ongoing development. The release is positive for the company but likely limited in near-term market impact given the preliminary nature of the data.
AC Immune reported new preliminary Phase 1 data for its TDP43-PET tracer ACI-19626, showing higher uptake in patients with ALS. The update is an early clinical-stage signal for the imaging program and supports ongoing development. The release is positive for the company but likely limited in near-term market impact given the preliminary nature of the data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
